This proposal provides a means of laying the groundwork for the candidate's career in scleroderma research. Her formal Ph.D. training was primarily in pharmacology and receptor signaling. She has developed an interest in proteomics technologies and wants to apply them to scleroderma research. In the course of this award period, the candidate expects to develop skills in the areas of rheumatology, biology of scleroderma fibroblasts, mass spectrometry, and proteomics that are much needed, through both didactic and laboratory experience. Then, using these new skills in combination with her receptor pharmacology and signal transduction background, she will develop independent research projects investigating the fundamental mechanisms of scleroderma fibrosis. Toward these ends, a proposal has been prepared which should provide ample opportunity to develop new skills and to obtain the theoretical background in scleroderma research required for the candidate's long-term goals. The research plan of the proposal is based on the observations that connective tissue growth factor (CTGF) Specifically binds numerous proteins in lung fibroblasts derived from scleroderma patients. CTGF is highly expressed in many fibrotic disorders and is considered to be a molecular marker of fibrosis. Interstitial lung fibrosis strikes up to 80% of scleroderma patients and is now the leading cause of death. Since scleroderma lung fibroblasts not only synthesize increased amounts of CTGF, but also contain proteins that specifically interact with CTGF, we postulate that such interactions are critical for the pathogenesis and expansion of scleroderma pulmonary fibrosis. Our research plan aims to identify the CTGF-interacting proteins and to define the components of a signal transduction complex for CTGF in scleroderma lung fibroblasts. This project will involve a combination of biochemical and proteomic techniques applied to the detailed reconstruction of CTGF's microenvironment in scleroderma lung fibroblasts. Part of the proposed studies will be carried out with BIAcore 3000, which allows detection of even transient binding of proteins. The use of this commercial instrument in this manner is a novel technique, which is not commonly available. An additional factor that makes this proposal particularly unique is the availability of the well-equipped Mass Spectrometry Facility, which offers instrumentation to sequence proteins at picomolar levels and lower. Cutting-edge proteomics technologies will allow us to identify CTGF-interacting proteins resolved via ID or 2D gel electrophoresis or eluted from the BIAcore sensor chip, as well as to spot the complex of protein cross linked to CTGF. The identified protein(s) might serve then as potential target(s) in the treatment of scleroderma pulmonary fibrosis for which no proven, effective therapy currently exists.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01AR051052-03
Application #
7227106
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Mancini, Marie
Project Start
2005-05-01
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
3
Fiscal Year
2007
Total Cost
$119,481
Indirect Cost
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Silver, Richard M; Bogatkevich, Galina; Tourkina, Elena et al. (2012) Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol 24:642-8
Ludwicka-Bradley, Anna; Silver, Richard M; Bogatkevich, Galina S (2011) Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum 41:212-22
Bogatkevich, Galina S; Ludwicka-Bradley, Anna; Nietert, Paul J et al. (2011) Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 63:1416-25
Bogatkevich, Galina S; Ludwicka-Bradley, Anna; Silver, Richard M (2009) Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 60:3455-64
Bogatkevich, Galina S; Ludwicka-Bradley, Anna; Singleton, C Beth et al. (2008) Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 295:L603-11
Bogatkevich, Galina S; Ludwicka-Bradley, Anna; Highland, Kristin B et al. (2007) Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum 56:3468-77
Bogatkevich, Galina S; Ludwicka-Bradley, Anna; Highland, Kristin B et al. (2007) Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum 56:2432-42